MDGL vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SYRE Captures Institutional Edge (3โ1 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MDGL counters with relative strength in Valuation. Fundamentally, MDGL trades at 38.1x Forward P/E with -10.7% operating margin (+50.1% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MDGL sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MDGL | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.8B | $9.8B | Larger Scale | MDGL |
| Trailing P/E Ratio Valuation | 61.4x | N/M | Lower Multiple | MDGL |
| Forward P/E Ratio Valuation | 38.1x | N/M | Lower Multiple | MDGL |
| Revenue Growth (YoY) Growth | +50.1% | +0.0% | Higher Growth | MDGL |
| Operating Margin (TTM) Profitability | -10.7% | 0.0% | Higher Margin | SYRE |
| Net Profit Margin Profitability | -10.9% | 0.0% | Higher Margin | SYRE |
| Return on Equity (ROE) Capital Efficiency | -24.8% | -35.0% | Higher ROE | MDGL |
| 52-Week Range Position Momentum | 27% ($354โ$615) | 88% ($22โ$111) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 0.28ฮฒ ยท 49% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | MDGL |
| Unified Institutional Score Composite Signal | 47.6 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | MDGL |